Alzheimer's News Today Home | Alzheimer's News Today
2024年12月9日 · Axsome to ask FDA to approve AXS-05 for Alzheimer’s agitation. Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy AXS-05 as a treatment for agitation related to Alzheimer’s disease.
News Archives - Alzheimer's News Today
Modified Kisunla dosing shown to lower risk of ARIA-E in Alzheimer’s. Being started on a smaller dose of the approved early Alzheimer’s disease therapy Kisunla (donanemab) — by shifting one vial from the first to the third infusion treatment — reduces the risk of ARIA-E, or amyloid-related imaging abnormalities associated with brain swelling, among adults with the neurodegenerative ...
Signs of Alzheimer's reversed, eased after 3 months of TB006
2023年4月21日 · The findings expand on data from a completed Phase 2a trial (NCT05074498) that preceded the OLE (NCT05476783) that showed a month of TB006 improved clinical signs, but failed to reach statistical significance compared with a placebo. “The three month or longer treatment in the OLE led to disease reversal or stabilization in the majority of participants with mild, moderate to severe ...
Alzheimer's therapy foralumab nasal spray cleared by FDA for...
2024年7月11日 · Most patients who took foralumab nasal spray for at least six months as part of an expanded use program for nonactive secondary progressive MS saw a reduction in microglia activity in the brain. Patients also reported less fatigue, a common symptom of MS. “Given that nasal foralumab dampens microglial inflammation in subjects with advanced progressive MS and microglial activation is a ...
Topline results of Phase 3 studies of simufilam for Alzheimer's...
2024年2月8日 · Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s disease.. Top-line results from the RETHINK-ALZ trial (NCT04994483) are expected by the end of this year, according to simufilam’s developer Cassava Sciences.Results from the second study, REFOCUS-ALZ study (NCT05026177), are ...
ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’s
2023年9月22日 · These are the top-line findings of an ongoing Phase 2 clinical trial (NCT04693520), whose two-year data also showed that Alzheon’s experimental therapy preserved the hippocampus, a brain structure important for memory that is damaged first in Alzheimer’s.. Importantly, ALZ-801’s safety profile over two years continued to show no increased risk of brain swelling and bleeds, which have ...
Bryostatin found to slow cognitive decline in advanced Alzheimer’s
2023年9月29日 · These bryostatin-associated cognitive benefits over a placebo were maintained even four months after stopping treatment, the researchers noted — highlighting the long-term effects of the Synaptogenix experimental therapy. “There is a huge unmet need in the [Alzheimer’s] population for drugs oriented specifically to advanced and severe patients,” Alan Tuchman, MD, CEO of Synaptogenix ...
In early Alzheimer’s, Anavex 2-73 slows cognitive decline...
2023年9月15日 · The global Phase 2b/3 trial, called Anavex 2-73-AD-004 (NCT03790709), enrolled 509 people, ages 60-85, with mild cognitive impairments or mild dementia due to Alzheimer’s.The participants were randomly assigned to receive oral capsules of either one of two doses of Anavex 2-73 (338 patients) or a placebo (170 patients), once daily for …
Alzheimer's awareness organizers say it's 'Time to act' on global...
2024年9月19日 · A regional campaign in the Americas and Caribbean, in collaboration with the Pan American Health Organization, will include resources in English, French, Spanish, and Portuguese to accommodate the diversity of languages spoken throughout the region.. In the lead-up to World Alzheimer’s Day, the Alzheimer’s Association is calling on people to take part by donating or fundraising, or by ...
About Us – Alzheimer's News Today
Alzheimer’s News Today is a digital platform intended to provide the Alzheimer’s disease community with the most recent news and information on the disease, as well as first-hand community perspectives from our patient and caregiver columnists.. All articles on Alzheimer’s News Today are original content produced by in-house writers and editors.